Safety of rapid-acting insulin analogs versus regular human insulin

American Journal of the Medical Sciences

Volumn 344, Issue 2, 2012, Pages 136-141

  Kitabchi, Abbas E ^a   Gosmanov, Aidar R ^a  

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

Diabetes; Hypoglycemia; Insulin; Pharmacodynamics; Pharmacokinetics

Indexed keywords

INSULIN ANTIBODY; INSULIN ASPART; INSULIN DERIVATIVE; INSULIN GLARGINE; INSULIN GLULISINE; INSULIN LISPRO; ISOPHANE INSULIN; PIG INSULIN; RECOMBINANT HUMAN INSULIN; SHORT ACTING INSULIN; SOMATOMEDIN C;

CLINICAL TRIAL (TOPIC); DIABETIC KETOACIDOSIS; DRUG SAFETY; HUMAN; HYPERGLYCEMIA; INFORMATION RETRIEVAL; INSULIN DEPENDENT DIABETES MELLITUS; KIDNEY FAILURE; NON INSULIN DEPENDENT DIABETES MELLITUS; PROTEIN BLOOD LEVEL; REVIEW; STOMACH PARESIS;

EID: 84864353456     PISSN: 00029629     EISSN: 15382990     Source Type: Journal    
DOI: 10.1097/MAJ.0b013e3182449ff9     Document Type: Review

References (48)

1. Hirsch IB. Insulin analogues. N Engl J Med 2005;352:174-183. (Pubitemid 40096614)
2. Levy P. Insulin analogs or premixed insulin analogs in combination with oral agents for treatment of type 2 diabetes. MedGenMed 2007; 9:12.
3. Novo Nordisk Inc. NovoLog- (insulin aspart [rDNA origin] injection) [prescribing information]. Princeton, NJ: Novo Nordisk, Inc., November; 2010.
4. Sanofi-Aventis. Apidra (insulin glulisine) [prescribing information]. Bridgewater, NJ; 2009.
5. Eli Lilly and Company. Humalog- (insulin lispro injection, USP) [prescribing information]. Indianapolis, IN; May 18, 2011.
6. Owens DR. Insulin glulisine-the potential for improved glycaemic control. Br J Diab Vasc Dis 2007;7:60-66. (Pubitemid 46779537)
7. Hermansen K, Fontaine P, Kukolja KK, et al. Insulin analogues (insulin detemir and insulin aspart) versus traditional human insulins (NPH insulin and regular human insulin) in basal-bolus therapy for patients with type 1 diabetes. Diabetologia 2004;47:622-629. (Pubitemid 38658363)
8. Gagnon-Auger M, du SP, Baillargeon JP, et al. Dose-dependent delay of the hypoglycemic effect of short-acting insulin analogs in obese subjects with type 2 diabetes: A pharmacokinetic and pharmacodynamic study. Diabetes Care 2010;33:2502-2507.
9. Singh SR, Ahmad F, Lal A, et al. Efficacy and safety of insulin analogues for the management of diabetes mellitus: A meta-analysis. CMAJ 2009;180:385-397.
10. Gough SC. A review of human and analogue insulin trials. Diabetes Res Clin Pract 2007;77:1-15. (Pubitemid 46590471)
11. Home PD, Lindholm A, Hylleberg B, et al. Improved glycemic control with insulin aspart: A multicenter randomized double-blind crossover trial in type 1 diabetic patients. Diabetes Care 1998;21:1904-1909. (Pubitemid 28478291)
12. Luijf YM, van Bon AC, Hoekstra JB, et al. Premeal injection of rapid-acting insulin reduces postprandial glycemic excursions in type 1 diabetes. Diabetes Care 2010;33:2152-2155.
13. American Diabetes Association. Standards of medical care in diabetes-2011. Diabetes Care 2011;34(suppl 1):S11-61.
14. Wright RJ, Newby DE, Stirling D, et al. Effects of acute insulininduced hypoglycemia on indices of inflammation: Putative mechanism for aggravating vascular disease in diabetes. Diabetes Care 2010;33: 1591-7.
15. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med 1993;329:977-986.
16. UK Prospective Diabetes Study Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837-853.
17. Skyler JS, Bergenstal R, Bonow RO, et al. Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA diabetes trials: A position statement of the American Diabetes Association and a scientific statement of the American College of Cardiology Foundation and the American Heart Association. Diabetes Care 2009;32:187-192.
18. Zoungas S, Patel A, Chalmers J, et al. Severe hypoglycemia and risks of vascular events and death. N Engl J Med 2010;363: 1410-8.
19. Patel A, MacMahon S, Chalmers J, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008;358:2560-2572. (Pubitemid 351831357)
20. Gerstein HC, Miller ME, Byington RP, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008;358: 2545-59. (Pubitemid 351831356)
21. Meyer C, Boron A, Plummer E, et al. Glulisine versus human regular insulin in combination with glargine in noncritically ill hospitalized patients with type 2 diabetes: A randomized double-blind study. Diabetes Care 2010;33:2496-2501.
22. Ceriello A, Colagiuri S. International Diabetes Federation guideline for management of postmeal glucose: A review of recommendations. Diabet Med 2008;25:1151-1156.
23. Schrot RJ. Targeting plasma glucose: Preprandial versus postprandial. Clin Diabetes 2004;22:169-172.
24. Miyazaki Y, Akasaka H, Ohnishi H, et al. Differences in insulin action and secretion, plasma lipids and blood pressure levels between impaired fasting glucose and impaired glucose tolerance in Japanese subjects. Hypertens Res 2008;31:1357-1363.
25. Festa A, D'Agostino R Jr, Mykkänen L, et al. Relative contribution of insulin and its precursors to fibrinogen and PAI-1 in a large population with different states of glucose tolerance. The insulin resistance atherosclerosis study (IRAS). Arterioscler Thromb Vasc Biol 1999;19: 562-8. (Pubitemid 29135156)
26. Oizumi T, Daimon M, Jimbu Y, et al. Impaired glucose tolerance is a risk factor for stroke in a Japanese sample-the Funagata study. Metabolism 2008;57:333-338. (Pubitemid 351178722)
27. Shaw JE, Hodge AM, De Courten M, et al. Isolated post-challenge hyperglycaemia confirmed as a risk factor for mortality. Diabetologia 1999;42:1050-1054. (Pubitemid 29408800)
28. Evans M, Schumm-Draeger PM, Vora J, et al. A review of modern insulin analogue pharmacokinetic and pharmacodynamic profiles in type 2 diabetes: improvements and limitations. Diabetes Obes Metab 2011;13:677-684.
29. Rossetti P, Porcellati F, Fanelli CG, et al. Superiority of insulin analogues versus human insulin in the treatment of diabetes mellitus. Arch Physiol Biochem 2008;114:3-10. (Pubitemid 351998751)
30. Bolli GB, Di Marchi RD, Park GD, et al. Insulin analogues and their potential in the management of diabetes mellitus. Diabetologia 1999;42: 1151-67. (Pubitemid 29459810)
31. Frid A, Hirsch L, Gaspar R, et al. New injection recommendations for patients with diabetes. Diabetes Metab 2010;36(suppl 1):S3-18.
32. Heinemann L, Weyer C, Rauhaus M, et al. Variability of the metabolic effect of soluble insulin and the rapid-acting insulin analog insulin aspart. Diabetes Care 1998;21:1910-1914. (Pubitemid 28478292)
33. Umpierrez GE, Jones S, Smiley D, et al. Insulin analogs versus human insulin in the treatment of patients with diabetic ketoacidosis: A randomized controlled trial. Diabetes Care 2009;32:1164-1169.
34. Hod M, Damm P, Kaaja R, et al. Fetal and perinatal outcomes in type 1 diabetes pregnancy: A randomized study comparing insulin aspart with human insulin in 322 subjects. Am J Obstet Gynecol 2008;198: 186.e1-7.
35. Heller S, Damm P, Mersebach H, et al. Hypoglycemia in type 1 diabetic pregnancy: The role of preconception insulin aspart treatment in a randomized study. Diabetes Care 2010;33:473-477.
36. Mathiesen ER, Kinsley B, Amiel SA, et al. Maternal glycemic control and hypoglycemia in type 1 diabetic pregnancy: A randomized trial of insulin aspart versus human insulin in 322 pregnant women. Diabetes Care 2007;30:771-776. (Pubitemid 46556565)
37. Kinsley B. Achieving better outcomes in pregnancies complicated by type 1 and type 2 diabetes mellitus. Clin Ther 2007;29(suppl D):S153-60.
38. Di Cianni G, Volpe L, Ghio A, et al. Maternal metabolic control and perinatal outcome in women with gestational diabetes mellitus treated with lispro or aspart insulin: comparison with regular insulin. Diabetes Care 2007;30: E11. (Pubitemid 46556613)
39. Shrishrimal K, Hart P, Michota F. Managing diabetes in hemodialysis patients: observations and recommendations. Cleve Clin J Med 2009;76:649-655.
40. Aisenpreis U, Pfutzner A, Giehl M, et al. Pharmacokinetics and pharmacodynamics of insulin Lispro compared with regular insulin in haemodialysis patients with diabetes mellitus. Nephrol Dial Transplant 1999;14(suppl 4):5-6. (Pubitemid 29358840)
41. Yanai H, Adachi H, Hamasaki H. Diabetic ketosis caused by the insulin analog aspart-induced anti-insulin antibody: successful treatment with the newest insulin analog glulisine. Diabetes Care 2011;34:e108.
42. Fineberg SE, Huang J, Brunelle R, et al. Effect of long-term exposure to insulin lispro on the induction of antibody response in patients with type 1 or type 2 diabetes. Diabetes Care 2003;26:89-96. (Pubitemid 36928999)
43. Kawamori R, Kadowaki T, Ishii H, et al. Efficacy and safety of insulin glulisine in Japanese patients with type 1 diabetes mellitus. Diabetes Obes Metab 2009;11:891-899.
44. Mianowska B, Szadkowska A, Pietrzak I, et al. Immunogenicity of different brands of human insulin and rapid-acting insulin analogs in insulin-naive children with type 1 diabetes. Pediatr Diabetes 2011;12: 78-84.
45. Brock Jacobsen I, Vind BF, Korsholm L, et al. Counter-regulatory hormone responses to spontaneous hypoglycaemia during treatment with insulin aspart or human soluble insulin: A double-blinded randomised cross-over study. Acta Physiol 2011;202:337-347.
46. Dreyer M, Prager R, Robinson A, et al. Efficacy and safety of insulin glulisine in patients with type 1 diabetes. Horm Metab Res 2005;37:702-707. (Pubitemid 41810494)
47. Kurtzhals P, Schaffer L, Sorensen A, et al. Correlations of receptor binding and metabolic and mitogenic potencies of insulin analogs designed for clinical use. Diabetes 2000;49:999-1005. (Pubitemid 30349423)
48. Miles HL, Acerini CL. Insulin analog preparations and their use in children and adolescents with type 1 diabetes mellitus. Paediatr Drugs 2008;10:163-176. (Pubitemid 351629672)